Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial.
- DOI
- 10.1016/j.eclinm.2026.103820
- Published
- 2026 Mar
- Container
- EClinicalMedicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.eclinm.2026.103820,
title = {Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial.},
author = {Vermeire S and Allegretti JR and Kim HJ and Long MD and Leszczyszyn J and Schreiber S and Kierkus J and Chandler PD and Ramakrishna J and Peeva E and Vincent MS and Shojaee N and Mahling P and Banfield C and Banerjee A and Gale JD and Hung KE},
year = {2026},
journal = {EClinicalMedicine},
doi = {10.1016/j.eclinm.2026.103820},
url = {https://doi.org/10.1016/j.eclinm.2026.103820}
}RIS
TY - JOUR TI - Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial. AU - Vermeire S AU - Allegretti JR AU - Kim HJ AU - Long MD AU - Leszczyszyn J AU - Schreiber S AU - Kierkus J AU - Chandler PD AU - Ramakrishna J AU - Peeva E AU - Vincent MS AU - Shojaee N AU - Mahling P AU - Banfield C AU - Banerjee A AU - Gale JD AU - Hung KE PY - 2026 JO - EClinicalMedicine DO - 10.1016/j.eclinm.2026.103820 UR - https://doi.org/10.1016/j.eclinm.2026.103820 ER -
APA
S, V., JR, A., HJ, K., MD, L., J, L., S, S., J, K., PD, C., J, R., E, P., MS, V., N, S., P, M., C, B., A, B., JD, G., & KE, H. (2026). Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.103820
Source records
- pubmed · retrieved 2026-09-26T06:27:59.070Z